Nektar Therapeutics

NKTR 
(NASDAQ) 
 
$ 33.42 <%= Resources.Global.txtUp %>
Updated 20/05/2019
Change % 3.95% Stock price increasing
Change 1.27 Stock price increasing
Volume 955,346
High $ 33.47
Low $ 32.33
Open $ 32.33
ISIN
Prev close $ 32.15
# of shares 174.31M
Market cap 5,825.34M USD
Intraday

Market closed
Nektar Therapeutics
Market is closed, opens at 14:30
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  33.42 -1.4% Stock price decreasing 7.8% Stock price increasing -16.6% Stock price decreasing -10.5% Stock price decreasing -59.2% Stock price decreasing
Powered by TradingView

News about Nektar Therapeutics

  • English
  • Regulatory news
05 Mar
 
04 Mar
 
15 Feb
 
31 Dec
 
31 Dec
 
29 Dec
 
28 Dec
 
27 Dec
 
26 Dec
 
26 Dec
 

Company profile

Nektar Therapeutics is a San Francisco-based emerging biotechnology company specializing in PEGylation technology. Its portfolio includes PEGylated biologics in immuno-oncology, chronic pain, hemophilia, breast cancer, and autoimmune disease. The company partners with several large pharmaceutical and biotechnology companies to co-develop therapies in a range of indications, which includes a collaboration with Bristol-Myers Squibb to develop bempegaldesleukin, the firm's leading immuno-oncology candidate, in combination with Bristol's Opdivo.

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
22 May 2019 02:42:07
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190514.2 - EUROWEB3 - 2019-05-22 03:42:07 - 2019-05-22 02:42:07 - 1000 - Website: OKAY